View Comments
UK-MARKETS-BRITAIN-STOCKS:Weaker FTSE 100 gets support from ABF and AstraZeneca
Reuters The London Stock Exchange building is seen in central London September 24, 2009. REUTERS/Stephen Hird

By Tricia Wright

LONDON (Reuters) - U.S. expansion plans for Associated British Foods and expectations of consolidation in the drugs sector kept FTSE 100 near a two-week high on Wednesday.

Clothing and food conglomerate AB Foods surged 8.8 percent, its best one-day percentage gain for 14 years, after saying its fast-growing clothing chain Primark is to set up in the United States, while posting higher interim profits.

Panmure Gordon lifted its rating on AB Foods to "buy" from "hold".

Persistent bid speculation lifted AstraZeneca by 2.1 percent, and together ABF and AstraZeneca added most points to the FTSE 100, in solid trading volumes, at around twice their 90-day daily averages.

"Associated British Foods have come out with a strong set of numbers, while with AstraZeneca, the bid speculation is the key headline that's still in the background," London-based Prime Wealth Group senior trader Dafydd Davies said.

AstraZeneca's rise built on a 4.7 percent gain on Tuesday, after The Sunday Times reported a possible $100 billion bid from Pfizer.

Both companies declined to comment on the report, but the prospect of deal-making in the sector also lifted Shire and GlaxoSmithKline for a second consecutive day.

The FTSE 100 - which on Tuesday hit its highest intra-day level since April 4, at 6,706.19 - closed down 7.02 points, or 0.1 percent, at 6,674.74 points.

Stocks trading without their latest dividend accounted for all of the index's points drop, with Aggreko, Antofagasta, BG, Centrica, Legal & General, Mondi, Old Mutual and Rolls Royce knocking off 8.7 points.

While some analysts said that a rebound in corporate dealmaking could offset concerns surrounding British firms in terms of frothy valuations and a slashing of analyst forecasts, the FTSE 100 is likely to be stuck in a range in the near term.

The index is trading on a 12-month forward price/earnings ratio of 13.2, against its five-year average of 11 times, Thomson Reuters Datastream shows.

Analysts have been steadily lowering profit forecasts since the start of 2014, data from Thomson Reuters Datastream shows.

"We're churning around in a trading range of 6,200 to 6,800," Richard Buxton, head of UK equities at Old Mutual Global Investors, said.

"The market needs further evidence of growth in corporate profits to underpin an assault of the all-time high of just under 7,000," he added.

The FTSE 100 hit a peak of 6,867 points in late January, near its highest level since early 2000, but has since slipped back due to concerns over a slump in emerging economies and tensions between Russia and Western powers over Ukraine.

Hantec Markets analyst Richard Perry said that if the FTSE did not break above 6,706 points - the high point from earlier in April - its near-term progress could be limited.

"If it does not get above 6,706 points, it could send out a bit of a sell signal," he said.

(Additional reporting by Sudip Kar-Gupta; Editing by Ruth Pitchford)